Aquestive Therapeutics Shares Rise 12% on Anaphylm Trial Timeline
21 September 2023 - 12:57AM
Dow Jones News
By Denny Jacob
Aquestive Therapeutics shares rose 12% to $1.72 on news it
expects to continue starting its clinical trial of oral epinephrine
product candidate anaphylm in the fourth quarter.
The stock is up 91% on the year so far through Wednesday's
trading session.
The pharmaceutical company said it intends to commence the trial
in the fourth quarter following alignment with the Food and Drug
Administration. It noted its current development plan continues to
include a standard repeat-dose study of anaphylm and an
already-approved comparator.
Chief Executive Daniel Barber said Aquestive is focused on the
work necessary to reach its goal of filing its new drug application
in 2024. He added that anaphylm has demonstrated clinical results
comparable to other known autoinjectors such as the EpiPen and
Auvi-Q for the emergency treatment of severe allergic reactions
including anaphylaxis.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
September 20, 2023 10:42 ET (14:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Dec 2024 to Jan 2025
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Jan 2024 to Jan 2025
